(SAN ANTONIO) November 1, 2022 –– The Theresa Mays Endowed Merit Award has been established to promote the education and advancement of oncology research for pharmacists. The award has been established with the support of friends and colleagues to recognize the life and legacy of Theresa Mays, BS, PharmD, BCOP, FASHP, and Vice President of Investigational Drug Services at NEXT Oncology.
The award, established in collaboration with Conquer Cancer, the ASCO Foundation, is intended to be given each year to a promising investigator, as determined by the then-applicable scientific review process for Conquer Cancer Merit Awards, with a preference for recipients who hold a PharmD degree. If there is not an eligible recipient who meets this preference, the award will be given to an eligible recipient planning an investigative career in pancreatic cancer.
Mays began her research career with internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, more than 22 years ago. She was diagnosed with pancreatic cancer in May 2022 and is honored to have this endowed award created in her honor.
“It is my hope that this award will help pharmacists get the education that wasn’t available to me when I started my career to be able to interact with patients on clinical trials. I have always found my inspiration from patients on clinical trials,” said Mays. “This offers hope to me and others on the cancer journey. My goal is that this helps provide additional opportunities for people with cancer and to potentially extend their quality of life.”
“Theresa is an outstanding and dedicated cancer researcher and pharmacist,” Dr. Tolcher said. “Theresa and I have worked together for many years. She has impacted the lives of many cancer patients, and this award is a way to say thank you and carry her legacy of advancing new drug therapies forward for the next generation of pharmacists in clinical research.”
Abstract submissions for ASCO’s 2023 Annual Meeting open this month. Details of the award requirements, policies and guidelines for abstract submissions can be found at ASCO 2023 Conference website.
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT is partnered with
Texas Oncology, the largest private oncology practice in the United States with more than 400 referring oncologists and US Oncology, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.
ssions open in November for ASCO 2023 Annual Meeting